News
CLDX
38.53
-2.78%
-1.10
Health Care Sector Update for 04/17/2024: VNDA, CLDX, NRBO
NASDAQ · 1d ago
Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target
Benzinga · 1d ago
Celldex’s Barzolvolimab Shows Promise for Urticaria Treatment: A Strong Buy Recommendation
TipRanks · 1d ago
CELLDEX ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2 STUDY OF BARZOLVOLIMAB IN PATIENTS WITH CHRONIC INDUCIBLE URTICARIA
Reuters · 1d ago
Weekly Report: what happened at CLDX last week (0408-0412)?
Weekly Report · 3d ago
Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
NASDAQ · 04/09 13:35
All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy
NASDAQ · 04/08 16:00
Weekly Report: what happened at CLDX last week (0401-0405)?
Weekly Report · 04/08 11:17
Weekly Report: what happened at CLDX last week (0325-0329)?
Weekly Report · 04/01 11:14
Weekly Report: what happened at CLDX last week (0318-0322)?
Weekly Report · 03/25 11:17
Celldex Therapeutics Price Target Maintained With a $67.00/Share by Cantor Fitzgerald
Dow Jones · 03/22 18:01
Cantor Fitzgerald Reiterates Overweight on Celldex Therapeutics, Maintains $67 Price Target
Benzinga · 03/22 17:51
Weekly Report: what happened at CLDX last week (0311-0315)?
Weekly Report · 03/18 11:15
Market-Moving News for March 15th
Madrigal Pharmaceuticals shares are trading higher after FDA approval of Rezdiffra. Cardlytics shares are higher after the company reported better-than-expected Q4 revenue. Adobe shares are lower after reporting weak guidance and poor financial results. The company's stock is down 12% in the past week.
Benzinga · 03/15 12:36
Weekly Report: what happened at CLDX last week (0304-0308)?
Weekly Report · 03/11 11:12
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Barchart · 03/08 06:00
Notable Wednesday Option Activity: CLDX, GOOG, PSFE
NASDAQ · 03/06 20:37
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
Celldex Therapeutics, Inc. Will participate in an “Inflammation & Immunology Corporate Panel Discussion” at TD Cowen’s 44th Annual Health Care Conference. The panel will be held on March 5, 2024. Anthony S. Marucci, President and Chief Executive Officer of Celldex will participate.
Barchart · 03/05 09:30
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Celldex Therapeutics, Inc. Announced the closing of its previously announced underwritten public offering of 9,798,000 shares of its common stock. The gross proceeds to Celldex from this offering were approximately $460.5 million. All of the shares sold in the offering were sold by celldex.
Barchart · 03/05 09:10
More
Webull provides a variety of real-time CLDX stock news. You can receive the latest news about Celldex Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CLDX
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.